Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Risk factors for acquisition of SARS-CoV-2 Omicron variant among a prospective cohort of French Healthcare Workers: impact of hybrid immunity.

Scientific reports·2026

Same author

Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.

Oncoimmunology·2026

Same author

Importance of the delivery route for the tolerability and efficacy of immunomodulatory agents for lung cancer.

Scientific reports·2026

Same author

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

Cell·2026

Same author

Engineering interleukin-10 for therapeutic applications.

International review of cell and molecular biology·2026

Same author

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

Nature·2026

Same journal

Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform.

Oncoimmunology·2026

Same journal

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.

Oncoimmunology·2026

Same journal

The peripheral immune landscape of human breast cancer.

Oncoimmunology·2026

Same journal

Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity.

Oncoimmunology·2026

Same journal

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Oncoimmunology·2026

Same journal

Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.

Oncoimmunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 13, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Trial watch: Dendritic cell-based anticancer therapy.

Norma Bloy¹, Jonathan Pol², Fernando Aranda²

¹Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM , U1138; Paris France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris France ; Université Paris-Sud/Paris XI ; Orsay, France.

|May 6, 2015

Summary

This summary is machine-generated.

Dendritic cell (DC) therapies are explored for cancer treatment, involving exposing DCs to tumor antigens before patient reintroduction or targeting DCs in vivo. These approaches aim to activate anti-tumor immunity, with one DC therapy approved for human use.

Keywords:

DC, dendritic cell DC-based vaccination FDA, Food and Drug Administration IFN, interferon MRC1, mannose receptor, C type 1 MUC1, mucin 1 TAA, tumor-associated antigen TLR, Toll-like receptor Toll-like receptor agonists Treg, regulatory T cell WT1, Wilms tumor 1 antigen cross-presentation autophagy iDC, immature DC immunogenic cell death mDC, mature DC pDC, plasmacytoid DC regulatory T cells

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Related Experiment Videos

Last Updated: Apr 13, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Dendritic cells (DCs) play a crucial role in regulating immune responses.
Patient-derived DCs are investigated for cancer immunotherapy.
Existing strategies involve ex vivo manipulation or in vivo targeting of DCs.

Conclusions:

Dendritic cell-based cancer therapeutics continue to be a high-interest area.
Further research and clinical development are ongoing for novel DC-based immunotherapies.
DCs hold significant promise for developing effective anticancer strategies.